tradingkey.logo
tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
View Detailed Chart
2.860USD
0.0000.00%
Close 03/27, 16:00ETQuotes delayed by 15 min
254.44MMarket Cap
LossP/E TTM

Maravai LifeSciences Holdings Inc

2.860
0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-4.03%

1 Month

-19.66%

6 Months

+1.06%

Year to Date

-12.00%

1 Year

+21.19%

View Detailed Chart

Key Insights

Maravai LifeSciences Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.33.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking
61 / 391
Overall Ranking
170 / 4542
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Fairly Valued
The company’s latest PE is -3.16, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 130.99M shares, decreasing 22.71% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 14.30K shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
4.333
Target Price
+40.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Maravai LifeSciences Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Maravai LifeSciences Holdings Inc Info

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Ticker SymbolMRVI
CompanyMaravai LifeSciences Holdings Inc
CEOBrust (Bernd)
Websitehttps://www.maravai.com/
KeyAI